<DOC>
	<DOCNO>NCT03099187</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety pirfenidone participant fibrosing interstitial lung disease ( ILD ) classify moderate high confidence category fibrosing ILD multidisciplinary team ( MDT ) review ( `` unclassifiable '' ILD ) .</brief_summary>
	<brief_title>A Study Pirfenidone Patients With Unclassifiable Progressive Fibrosing Interstitial Lung Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Interstitial</mesh_term>
	<mesh_term>Pirfenidone</mesh_term>
	<criteria>Age &gt; = 1885 year Confirmed fibrosing ILD , follow multidisciplinary team review , classify either high moderate confidence specific idiopathic interstitial pneumonia define ILD Progressive disease consider investigator participant deterioration within last 6 month , define rate decline force vital capacity ( FVC ) &gt; 5 % significant symptomatic worsening due cardiac , pulmonary vascular cause Extent fibrosis &gt; 10 % highresolution compute tomography Forced vital capacity &gt; = 45 % predict value Diffusing capacity lung carbon monoxide ( DLco ) &gt; = 30 % predict value Forced expiratory volume 1 second/FVC ratio &gt; = 0.7 Able 6minute walk distance ( 6MWD ) &gt; = 150 meter For woman childbearing potential : agreement remain abstinent use nonhormonal hormonal contraceptive method failure rate &lt; 1 % per year treatment period least 90 day last dose pirfenidone For men , agreement remain abstinent use contraceptive measure , agreement refrain donate sperm Diagnosis moderate high confidence nonspecific interstitial pneumonia ILD identifiable cause connective tissue diseaseILD , chronic hypersensitivity pneumonitis , others Diagnosis idiopathic pulmonary fibrosis independent confidence level History unstable angina myocardial infarction previous 6 month Treatment high dose systemic corticosteroid , immunosuppressant mycophenolate mofetil/acid ( MMF ) , time within 4 week screen period . Participants treat MMF stable dose expect remain stable throughout trial start least 3 month prior screen Participants previously treat pirfenidone nintedanib Participants treat Nacetylcysteine fibrotic lung disease , time within 4 week screening period Drug treatment type pulmonary hypertension Participation trial investigational medicinal product within last 4 week Significant organ comorbidity include hepatic renal impairment Predicted life expectancy &lt; 12 month active transplant wait list Use tobacco product 12 week prior start screen , unwillingness abstain use Followup Visit Illicit drug alcohol abuse within 12 month prior screen Planned major surgery trial Hypersensitivity active substance excipients pirfenidone History angioedema Concomitant use fluvoxamine Clinical evidence active infection Any history hepatic impairment , elevation transaminase enzyme , liver function test result : Total bilirubin upper limit normal ( ULN ) , Aspartate aminotransferase alanine aminotransferase &gt; 1.5 × ULN , Alkaline phosphatase &gt; 2.0 × ULN Creatinine clearance &lt; 30 milliliter ( mL ) per minute , calculate use CockcroftGault formula Any serious medical condition , clinically significant abnormality Electrocardiogram ( ECG ) screening , laboratory test result An ECG heart rate correct QT interval use Fridericia 's formula &gt; = 500 millisecond screen , family personal history long QT syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>